Literature DB >> 17138252

Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome.

Doruk Erkan1.   

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rapidly progressive life-threatening disease that causes multiple organ thromboses in the presence of antiphospholipid antibodies. High index of clinical suspicion and careful investigation are required to make an early diagnosis so that treatment with anticoagulation, corticosteroids, and plasma exchange or intravenous immunoglobulins can be initiated. Despite this multi-modal treatment, CAPS is associated with high mortality; evidence-based management recommendations do not exist due to the rarity of the condition and the lack of controlled studies. This article reviews the therapeutic and prognostic controversies that were addressed during the 1st International Symposium on CAPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17138252     DOI: 10.1016/j.autrev.2006.06.013

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  13 in total

1.  Catastrophic antiphospholipid syndrome triggered by sepsis.

Authors:  Susan Kim; Neal K Moskowitz; Edward F DiCarlo; Anne R Bass; Doruk Erkan; Michael D Lockshin
Journal:  HSS J       Date:  2008-12-19

2.  The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems.

Authors:  Ljudmila Stojanovich
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

4.  Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases.

Authors:  Gisele Zandman-Goddard; Alexander Krauthammer; Yair Levy; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 5.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

6.  Recurrent thrombotic events after catastrophic antiphopholipid syndrome.

Authors:  Hayne Cho Park; Hyun-Bae Yoon; Tae Woo Lee; Ji Yong Jung; Ho Jun Chin; Yon Su Kim; Suhnggwon Kim
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

Review 7.  Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.

Authors:  Sanjeev Baweja; Kate Wiggins; Darren Lee; Susan Blair; Margaret Fraenkel; Lawrence P McMahon
Journal:  J Artif Organs       Date:  2010-12-10       Impact factor: 1.731

Review 8.  Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection.

Authors:  Mark P Plummer; Adam M H Young; Ronan O'Leary; Maxwell S Damian; Andrea Lavinio
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

Review 9.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 10.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.